肠易激综合征疗效系统评价:需治疗人数或为误导性指标
结果显示FDA终点NNT平均比主观终点高2个单位(P<0.01),标准化终点后不同适应症NNT相似,提示终点异质性可能扭曲疗效比较。
要点
- FDA终点NNT平均比主观充分缓解终点高2个单位(P<0.01)。
- 标准化终点后,便秘型、腹泻型及整体症状IBS的NNT分别为5、8、8。
- 忽略终点异质性可能扭曲IBS药物比较效益结论。
核心结论
- 使用标准化终点时,纳入的IBS药物在不同适应症间NNT相似。
- 未考虑试验终点异质性可能扭曲比较效益结论并影响临床决策。
研究设计与样本
- 纳入15项报告主观充分缓解和当代FDA终点的安慰剂对照IBS药物试验。
- 采用随机效应模型比较同一试验不同终点及同一终点不同适应症的NNT。
主要发现
- FDA终点NNT平均比主观充分整体缓解终点高2个单位(P<0.01)。
- 三环类药物与其他疗法之间NNT无显著差异(P=0.41)。
- 使用主观缓解终点纳入三环类时,便秘型IBS药物NNT为5(P<0.0001)。
- 腹泻型IBS药物NNT为8(P<0.0001),IBS整体症状药物NNT为8(P=0.001)。
临床怎么用
- 解读IBS药物NNT时应考虑试验终点差异,避免直接比较不同终点下的NNT。
- 标准化终点后NNT相似,可辅助临床在不同IBS适应症间比较药物疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Using the number needed to treat (NNT) to compare pharmacotherapies for irritable bowel syndrome (IBS) is complicated by evolving trial endpoints. Standardizing NNT estimates across these endpoints, including future development of a conversion framework linking historical subjective measures to contemporary Food and Drug Administration (FDA) response criteria, may improve the validity of therapeutic efficacy comparisons. METHODS: PubMed, Web of Science, and Cochrane databases were searched through October 2024 to identify placebo-controlled clinical trials investigating IBS pharmacotherapies that reported both the subjective adequate relief and contemporary FDA endpoints. Calculated NNTs were compared between different endpoints for the same trials and across the same endpoints for different indications using a random-effects model. RESULTS: Among the 15 included trials, the FDA endpoint NNT was on average 2 units higher than the subjective adequate global relief endpoint ( P < 0.01) and no significant NNT differences were noted between tricyclics and other therapies ( P = 0.41). When using the subjective relief endpoint to enable the inclusion of tricyclics, the NNTs for drugs for constipation-predominant IBS, diarrhea-predominant IBS, and IBS global symptoms were 5 ( P < 0.0001), 8 ( P < 0.0001), and 8 ( P = 0.001), respectively. DISCUSSION: When standardized endpoints are used, the NNTs for included IBS pharmacotherapies are similar across indications. Failure to account for endpoint heterogeneity in clinical trials for IBS may distort comparative effectiveness conclusions, undermining clinical decision-making.
引用
- Busam JA, Batta N, Rezaie A, et al. A Systematic Review of Efficacy in Irritable Bowel Syndrome: How the Number Needed to Treat May be a Misleading Metric. Am J Gastroenterol. 2026. PMID: 41705717. doi:10.14309/ajg.0000000000003968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。